{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T18:45:04Z","timestamp":1757616304091,"version":"3.44.0"},"reference-count":16,"publisher":"BMJ","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Fam Plann Reprod Health Care"],"published-print":{"date-parts":[[2010,4]]},"DOI":"10.1783\/147118910791069286","type":"journal-article","created":{"date-parts":[[2010,4,8]],"date-time":"2010-04-08T19:26:02Z","timestamp":1270754762000},"page":"106.3-107","source":"Crossref","is-referenced-by-count":7,"title":["Combined pill and GTD"],"prefix":"10.1136","volume":"36","author":[{"given":"Gillian","family":"Robinson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2010,4,1]]},"reference":[{"key":"ref_1","article-title":"Eligibility Criteria for Contraceptive Use","author":"Medical, U.K.","year":"2009","unstructured":"UK Medical Eligibility Criteria for Contraceptive Use (UKMEC 2009). 2009. http:\/\/www.fsrh.org\/admin\/uploads\/UKMEC2009.pdf [Accessed 10 February 2010]."},{"key":"ref_2","article-title":"Eligibility Criteria for Contraceptive Use","author":"Medical, U.K.","year":"2005","unstructured":"UK Medical Eligibility Criteria for Contraceptive Use (UKMEC 2005\/2006). 2006. http:\/\/www.fsrh.org\/admin\/uploads\/archive\/UKMEC2005_06.pdf [Accessed 10 February 2010]."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.contraception.2009.03.022","article-title":"COC and IUD use amongst women with gestational trophoblastic disease","volume":"80","author":"Gaffield, M.E.; Kapp, N.; Curtis, K.M.","year":"2009","unstructured":"Gaffield ME, Kapp N, Curtis KM. COC and IUD use amongst women with gestational trophoblastic disease. Contraception 2009; 80: 363\u2013371.","journal-title":"Contraception"},{"key":"ref_4","unstructured":"Reply In response to Dr Robinson\u2019s letter1 we can say that the use of combined hormonal contraception (CHC) in women with gestational trophoblastic disease (GTD) was extensively reviewed by a multidisciplinary working group of worldwide experts for the WHO Medical Eligibility Criteria (WHOMEC) update in 2009. As a result of this systematic review of published evidence, and taking into account the opinion of experts, a decision was made to advise a Category 1 (unrestricted use) for the use of CHC in women with GTD with decreasing or undetectable levels or indeed with persistently elevated levels or malignant disease.","article-title":"Reply In response to Dr Robinson\u2019s letter1 we can say that the use of combined hormonal contraception (CHC) in women with gestational trophoblastic disease (GTD) was extensively reviewed by a multidisciplinary working group of worldwide experts for the WHO Medical Eligibility Criteria (WHOMEC) update in 2009. As a result of this systematic review of published evidence, and taking into account the opinion of experts, a decision was made to advise a Category 1 (unrestricted use) for the use of CHC in women with GTD with decreasing or undetectable levels or indeed with persistently elevated levels or malignant disease"},{"key":"ref_5","unstructured":"The UK Medical Eligibility Criteria (UKMEC) Consensus Group, which included a variety of health professionals (including representation from the Royal College of Obstetricians and Gynaecologists, the Faculty of Sexual and Reproductive Healthcare, and general practice), agreed to uphold the new WHOMEC Category 1 for CHC use by women with GTD and persistently elevated serum human chorionic gonadotropin (hCG) levels or malignant disease. The UKMEC Consensus Group could find no evidence to support a Category 3 for the use of intrauterine contraception in women with decreasing or undetectable serum levels of hCG. As there is no evidence that use of intrauterine contraception by women with GTD and decreasing or undetectable serum levels of hCG poses any risk, a Category 1 was given as in the UKMEC 2005. The Gaffield review paper2 was published after the review of evidence in preparation of the UKMEC update and therefore was not quoted.","article-title":"The UK Medical Eligibility Criteria (UKMEC) Consensus Group, which included a variety of health professionals (including representation from the Royal College of Obstetricians and Gynaecologists, the Faculty of Sexual and Reproductive Healthcare, and general practice), agreed to uphold the new WHOMEC Category 1 for CHC use by women with GTD and persistently elevated serum human chorionic gonadotropin (hCG) levels or malignant disease. The UKMEC Consensus Group could find no evidence to support a Category 3 for the use of intrauterine contraception in women with decreasing or undetectable serum levels of hCG. As there is no evidence that use of intrauterine contraception by women with GTD and decreasing or undetectable serum levels of hCG poses any risk, a Category 1 was given as in the UKMEC 2005. The Gaffield review paper2 was published after the review of evidence in preparation of the UKMEC update and therefore was not quoted"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1783\/147118910791069286","article-title":"Combined pill and GTD","volume":"36","author":"Robinson, G.","year":"2010","unstructured":"Robinson G. Combined pill and GTD [Letter]. J Fam Plann Reprod Health Care 2010; 36: 106\u2013107.","journal-title":"J Fam Plann Reprod Health Care"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.contraception.2009.03.022","article-title":"COC and IUD use amongst women with gestational trophoblastic disease","volume":"80","author":"Gaffield, M.E.; Kapp, N.; Curtis, K.M.","year":"2009","unstructured":"Gaffield ME, Kapp N, Curtis KM. COC and IUD use amongst women with gestational trophoblastic disease. Contraception 2009; 80: 363\u2013371.","journal-title":"Contraception"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1783\/147118909789587178","article-title":"Localised lipoatrophy at the site of Implanon\u00a9 insertion","volume":"35","author":"Lindsay, P.","year":"2009","unstructured":"Lindsay P. Localised lipoatrophy at the site of Implanon\u00a9 insertion [Letter]. J Fam Plann Reprod Health Care 2009; 35: 266.","journal-title":"J Fam Plann Reprod Health Care"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1783\/147118909789587178","article-title":"Reply to \u201cLocalised lipoatrophy at the site of Implanon\u00a9 insertion\u201d","volume":"35","author":"Mohlala, B.; Falowo, F.","year":"2009","unstructured":"Mohlala B, Falowo F. Reply to \u201cLocalised lipoatrophy at the site of Implanon\u00a9 insertion\u201d [Letter]. J Fam Plann Reprod Health Care 2009; 35: 266.","journal-title":"J Fam Plann Reprod Health Care"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1783\/147118909789587178","article-title":"Localised lip atrophy at the site of Implanon\u00a9 insertion [Letter]","volume":"35","author":"Lindsay, P.","year":"2009","unstructured":"Lindsay P. Localised lip atrophy at the site of Implanon\u00a9 insertion [Letter] J Fam Plann Reprod Health Care 2009; 35: 266.","journal-title":"J Fam Plann Reprod Health Care"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1783\/147118910791069312","article-title":"Resolution of localised lipoatrophy at the Implanon\u00a9 insertion site","volume":"36","author":"Lindsay, P.","year":"2010","unstructured":"Lindsay P. Resolution of localised lipoatrophy at the Implanon\u00a9 insertion site [Letter]. J Fam Plann Reprod Health Care 2010; 36: 107.","journal-title":"J Fam Plann Reprod Health Care"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo, C.A.; Busto, U.; Sellers, E.M.; Sandor, P.; Ruiz, I.; Roberts, E.A.","year":"1981","unstructured":"Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239\u2013245.","journal-title":"Clin Pharmacol Ther"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1783\/147118909789587178","article-title":"Reply to \u201cLocalised lipoatrophy at the site of Implanon\u00a9 insertion\u201d","volume":"35","author":"Mohlala, B.; Falowo, F.","year":"2009","unstructured":"Mohlala B, Falowo F. Reply to \u201cLocalised lipoatrophy at the site of Implanon\u00a9 insertion\u201d [Letter]. J Fam Plann Reprod Health Care 2009; 35: 266.","journal-title":"J Fam Plann Reprod Health Care"},{"key":"ref_14","unstructured":"I would be interested to know whether any other Journal readers have used an expired IUD and, if so, what the outcome was. Was my colleague right to replace the IUD on this occasion?","article-title":"I would be interested to know whether any other Journal readers have used an expired IUD and, if so, what the outcome was. Was my colleague right to replace the IUD on this occasion?"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1783\/147118910791069439","article-title":"Reference 1 Yadava RP. Use of an expired Cu-IUD","volume":"36","author":"Letter","year":"2010","unstructured":"Reference 1 Yadava RP. Use of an expired Cu-IUD [Letter]. J Fam Plann Reprod Health Care 2010; 36: 107.","journal-title":"J Fam Plann Reprod Health Care"},{"issue":"2","key":"ref_16","article-title":"Fam Plann Reprod","volume":"36","author":"FSRH, J.","year":"2010","unstructured":"\u00a9FSRH J Fam Plann Reprod Health Care 2010: 36(2)","journal-title":"Health Care"}],"container-title":["Journal of Family Planning and Reproductive Health Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1783\/147118910791069286","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T17:57:35Z","timestamp":1757095055000},"score":1,"resource":{"primary":{"URL":"https:\/\/jfprhc.bmj.com\/lookup\/doi\/10.1783\/147118910791069286"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4]]},"references-count":16,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2010,4,1]]},"published-print":{"date-parts":[[2010,4]]}},"alternative-id":["10.1783\/147118910791069286"],"URL":"https:\/\/doi.org\/10.1783\/147118910791069286","relation":{},"ISSN":["1471-1893","2045-2098"],"issn-type":[{"type":"print","value":"1471-1893"},{"type":"electronic","value":"2045-2098"}],"subject":[],"published":{"date-parts":[[2010,4]]}}}